Date published: 2026-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

KIR6.1 CRISPR/Cas9 KO Plasmid (h): sc-401477

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • KIR6.1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the KIR6.1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    KIR6.1 CRISPR/Cas9 KO Plasmid (h)

    sc-401477
    20 µg
    $397.00

    Overview

    KCNJ8 encodes the inward-rectifier potassium channel subunit KIR6.1 (Kir6.1), a core component of ATP-sensitive potassium (KATP) channels that couple cellular metabolic state to membrane excitability. In many tissues, Kir6.1 partners with sulfonylurea receptor subunits to regulate potassium flux in response to changes in ATP/ADP, influencing vascular smooth muscle tone, cellular stress responses, and excitability-dependent signaling. By linking nucleotide sensing to ion conductance, KIR6.1 contributes to processes such as membrane potential stabilization, calcium handling, and bioenergetic homeostasis. Genetic and functional perturbations of KCNJ8 have been associated with channelopathies and cardiovascular phenotypes, supporting its relevance for mechanistic studies in excitable cells and metabolic signaling contexts.

    KIR6.1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KCNJ8 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KCNJ8 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KCNJ8 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish KIR6.1 protein expression.

    This CRISPR knockout system enables efficient generation of KCNJ8-deficient cell models for investigation of KIR6.1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting KCNJ8 exon(s) critical for KIR6.1 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple KCNJ8 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by KIR6.1 CRISPR/Cas9 KO Plasmid (h) and KIR6.1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KCNJ8 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by KIR6.1 HDR Plasmid (h) and KIR6.1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KCNJ8 homology arms to support homology-directed repair at defined KCNJ8 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.